In a journal

2. W.C. Appel, "Postmarketing Surveillance in Canada," Drug Information Journal 30 (3) 655–660 (1996).

In a newspaper

Online Source

4. M. Angell, "Is Academic Medicine for Sale," New England Journal of Medicine, 343 (7) 1516–1518 (2000), http://content.nejm.org/ (accessed February 12,2006).

In press

5. E.L. Posvar and A.J. Sedman, "First-in-Human Studies of Synthetic Molecules," Applied Clinical Trials (in press).

Book

6. B. Spilker, Guide to Clinical Trials, 2nd Edition, (Raven Press, New York, 1994).

Chapter in edited book

7. V.H.L. Lee, "Problems and Solutions in Peptide and Protein Drug Delivery," in Peptides, Peptoids, and Proteins, Vol.3, P. Garzone, W.A. Colburn, and M. Mokotoff, eds. (Harvey Whitney Books, Cincinnati, 1989), pp. 80–92.

Code of Federal Regulations

8. Code of Federal Regulations, Title 21, Part 56, Section 109(e) (U.S. Government Printing Office, Washington, DC).

Federal Register

8. Department of Health and Human Services, proposed rule: "Investigational New Drug Applications and New Drug Applications," Federal Register 60 (174), 46794 (8 September 1995).

Government publication

9. Food and Drug Administration, Guidelines for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, Part VI (FDA, Rockville, MD, 1993).

10. Food and Drug Administration, information sheet: Continuing Review after Study Approval (FDA, Rockville, MD, 1 October 2007).

Privately published booklet or report

11. 2002: Leadership in Biotechnology (J. Robert Scott, 27 State Street, Boston, MA 02109).